Across TCGA pan-cancer cohorts, SLC15A3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC15A3 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SLC15A3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC15A3 expression acts as an unfavorable survival marker.
COAD and LUSC are the cancer types where SLC15A3 Mutation most reproducibly stratifies survival.